WO2006034611A1 - Utilisation de la souche st-iii de lactobacillus plantarum dans la perte de poids - Google Patents
Utilisation de la souche st-iii de lactobacillus plantarum dans la perte de poids Download PDFInfo
- Publication number
- WO2006034611A1 WO2006034611A1 PCT/CN2005/000101 CN2005000101W WO2006034611A1 WO 2006034611 A1 WO2006034611 A1 WO 2006034611A1 CN 2005000101 W CN2005000101 W CN 2005000101W WO 2006034611 A1 WO2006034611 A1 WO 2006034611A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- iii
- lactobacillus plantarum
- weight
- group
- milk
- Prior art date
Links
- 241001462463 Lactobacillus plantarum ST-III Species 0.000 title claims description 13
- 230000037396 body weight Effects 0.000 claims description 17
- 235000013305 food Nutrition 0.000 claims description 8
- 230000036541 health Effects 0.000 claims description 6
- 235000013365 dairy product Nutrition 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims description 3
- 235000013361 beverage Nutrition 0.000 claims description 2
- 238000002360 preparation method Methods 0.000 claims description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 32
- 241000700159 Rattus Species 0.000 description 25
- 235000013336 milk Nutrition 0.000 description 24
- 239000008267 milk Substances 0.000 description 24
- 210000004080 milk Anatomy 0.000 description 24
- 230000000694 effects Effects 0.000 description 14
- 208000016261 weight loss Diseases 0.000 description 13
- 230000004580 weight loss Effects 0.000 description 13
- 235000012000 cholesterol Nutrition 0.000 description 11
- 238000012360 testing method Methods 0.000 description 11
- 241001465754 Metazoa Species 0.000 description 9
- 210000004369 blood Anatomy 0.000 description 9
- 239000008280 blood Substances 0.000 description 9
- 230000001276 controlling effect Effects 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 6
- 150000002632 lipids Chemical class 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 239000000843 powder Substances 0.000 description 6
- 108010023302 HDL Cholesterol Proteins 0.000 description 5
- 108010010234 HDL Lipoproteins Proteins 0.000 description 5
- 102000015779 HDL Lipoproteins Human genes 0.000 description 5
- 238000001543 one-way ANOVA Methods 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- 150000003626 triacylglycerols Chemical class 0.000 description 5
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 5
- 235000013312 flour Nutrition 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 3
- 108010022197 lipoprotein cholesterol Proteins 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- 102000002322 Egg Proteins Human genes 0.000 description 2
- 108010000912 Egg Proteins Proteins 0.000 description 2
- 240000006024 Lactobacillus plantarum Species 0.000 description 2
- 235000013965 Lactobacillus plantarum Nutrition 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 210000000577 adipose tissue Anatomy 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 239000000883 anti-obesity agent Substances 0.000 description 2
- 239000003833 bile salt Substances 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 235000013345 egg yolk Nutrition 0.000 description 2
- 210000002969 egg yolk Anatomy 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 229940072205 lactobacillus plantarum Drugs 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 238000004260 weight control Methods 0.000 description 2
- 235000013618 yogurt Nutrition 0.000 description 2
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 208000032928 Dyslipidaemia Diseases 0.000 description 1
- XYZZKVRWGOWVGO-UHFFFAOYSA-N Glycerol-phosphate Chemical compound OP(O)(O)=O.OCC(O)CO XYZZKVRWGOWVGO-UHFFFAOYSA-N 0.000 description 1
- 208000035150 Hypercholesterolemia Diseases 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010021639 Incontinence Diseases 0.000 description 1
- 208000017170 Lipid metabolism disease Diseases 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 235000014590 basal diet Nutrition 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 229940036811 bone meal Drugs 0.000 description 1
- 239000002374 bone meal Substances 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 235000012716 cod liver oil Nutrition 0.000 description 1
- 239000003026 cod liver oil Substances 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000005265 energy consumption Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 206010016766 flatulence Diseases 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000001071 malnutrition Effects 0.000 description 1
- 235000000824 malnutrition Nutrition 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 235000020124 milk-based beverage Nutrition 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 230000003880 negative regulation of appetite Effects 0.000 description 1
- 208000015380 nutritional deficiency disease Diseases 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 239000006041 probiotic Substances 0.000 description 1
- 235000018291 probiotics Nutrition 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 235000021404 traditional food Nutrition 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 235000015099 wheat brans Nutrition 0.000 description 1
- 235000008939 whole milk Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Definitions
- the present invention relates to a novel use of Lactobacillus plantarum ST-III, and more particularly to its use in the field of weight loss.
- weight loss drugs and weight loss health products are emerging one after another, but such products either stimulate fat metabolism and the burning of peripheral fat, or effectively reduce the body's absorption of food, and increase energy consumption to achieve weight loss, so for
- weight losers who are beautiful, long-term use affects their normal energy needs, and has adverse reactions such as oily stools, incontinence and flatulence; while some products cause dehydration through diarrhea and appetite suppression.
- Phenomenon or malnutrition leads to the reduction of active tissues. In addition to fat, it often reduces the active tissues such as muscles, internal organs, bones, and water in the body. This is the most serious point of wrong weight loss.
- controlling weight and losing weight is not simply a weight loss but a control or reduction of fat.
- the real weight loss success is to evaluate whether the body fat is effectively reduced before and after weight loss. Therefore, it is the most scientifically effective to reduce body fat, including lowering blood lipids, and then achieving control and weight loss. It is also the direction of developing such new products.
- the present inventors further studied the Lactobacillus plantarum ST-III CGMCC No. 0847, and found through animal experiments that the Lactobacillus plantarum ST-III of the present invention can not only lower serum cholesterol and increase high-density lipoprotein cholesterol content. Moreover, it also has the effect of controlling or losing weight, that is, assisting weight loss. It is therefore an object of the present invention to provide a new use of Lactobacillus plantarum ST-III CGMCC No. 0847.
- the present invention relates to the use of Lactobacillus plantarum ST-III CGMCC No. 0847 for the preparation of articles for controlling or reducing body weight.
- the product for controlling or losing weight may be a medicine, a health product or a food or beverage.
- the preferred food or drink may be a dairy product prepared by adding an effective amount of Lactobacillus plantarum ST-III CGMCC No. 0847 to a dairy product such as yogurt, yogurt, cheese, milk beverage or milk powder.
- Lactobacillus plantarum ST-III is a natural product selected from traditional Chinese foods. It has high-efficiency fat-reducing function and safety for long-term consumption. In addition, many obese people also suffer from high blood lipids. While Lactobacillus plantarum is losing weight, it can improve hyperlipidemia, repair both internal and external, comprehensively improve the health of consumers, and prevent cardiovascular diseases, diabetes and other metabolism. The occurrence of abnormal diseases improves the quality of life of consumers. detailed description
- SD rats are used to induce 1% cholesterol, 10% egg yolk powder, 10% lard and 0.2% pig bile salt in the basic feed. So rat hypercholesterolemia.
- ST-m active milk normal milk (commercially available pure fresh milk) was added to the high-activity Lactobacillus plantarum ST-III CGMCC No.0847 strain powder, the number of live bacteria reached 5 X 107cfu/ml], for feeding
- the normal milk containing no active ingredient was used as a control, and the body weight of the rat was measured every week.
- the blood lipid content such as serum cholesterol of the SD rat was detected to determine whether the strain has the effects of reducing the body weight of the rat and lowering the serum cholesterol.
- ST-III active milk that is, high-activity Lactobacillus plantarum ST-III CGMCC No.0847 strain powder was added to ordinary milk, and the number of live bacteria reached 5 X 107 cfo/ml.
- the experimental samples were concentrated 10 times for animal experiments. Store at 4 ° C for experimental use.
- mice 48 to 180 g clean grade SD (approved No. SCXK (Shanghai) 2003-0002) of 48 healthy male rats, according to serum cholesterol and triglycerides, were selected from Shanghai Xipuer-Beikai Experimental Animal Co., Ltd. The levels were randomly divided into 4 groups of 12 animals each.
- Dosage 200 ml per person (60 kg body weight) per day, equivalent to 3.3 ml/d kg body weight.
- Three dose groups of 21ml/kg.bw (body weight), 42ml/kg.bw> 125ml kg.bw and high-fat control group (Oml/) were designed according to the recommended intake of human body 5 times, 10 times and 30 times respectively.
- Kg.bw group The sample was concentrated 10 times (live number 5 X 108) and the corresponding dose was prepared with the control milk.
- the rats were administered once a day orally, and the blood lipid indexes were measured after 45 days of continuous gavage.
- the amount of gastric perfusion in rats was 10 ml/kg.bw.
- Rats were fed basal diet for 5 days in the experimental environment, and fasting blood was taken through the eye to determine the serum triglyceride, cholesterol and high-density lipoprotein cholesterol levels. According to serum cholesterol levels and considering the level of triglycerides, they were randomly divided into 4 groups: high-fat control group, low-, medium-, and high-dose groups. At the same time as the high-fat vocabulary was given, the test group was given the corresponding dose of ST-III active milk, and the high-fat control group was replaced with ordinary milk containing no active ingredient, and the stomach was administered daily for 45 days.
- SPSS10.0 software was used to test the homogeneity of variance of each experimental raw data.
- the data of the "variance variance” requirement was compared by one-way ANOVA with the mean of multiple experiments and one control group.
- the method performs statistical processing; performs appropriate variable conversion on data data with non-normal distribution or variance, and after the "normal variance” requirement is satisfied, the data obtained by the conversion is used for statistical processing.
- Basic feed composition Table 1
- the initial body weight of the rats was not significantly different between the 21 ml/kg.bw, 42 ml/kg.bw, 125 ml/kg.bw group and the Oml/kg.bw group (P>0.05). That is, the initial body weight of the rats was more balanced among the groups. Rats were given orally with different doses of ST-III active milk for 45 days. The weight of each dose group was tested for homogeneity of variance to meet the homogeneity of variance. One-way ANOVA and the mean between multiple experimental groups and one control group were used. The two-two comparison method is used for statistical processing. The body weight of the 125 ml/kg.bw group was significantly lower than that of the Oml/kg.bw group (P ⁇ 0.01).
- the number of animals in the group is the first weight ⁇ ⁇ Week 1 Week 2 Week 3 (g) ⁇ M4
- Rats were given orally with different doses of ST-III active milk for 45 days. Before and after the test, the serum cholesterol levels of the rats were tested for homogeneity of variance, and the homogeneity of variance was met. One-way ANOVA and multiple experiments were used. The two-two comparison method of the mean between the group and one control group was statistically processed. As can be seen from Table 3, the serum cholesterol levels in the 21 ml/kg.bw, 42 ml/kg.bw, and 125 ml/kg.bw groups were significantly lower than those in the Oml/kg.bw group (P ⁇ 0.01).
- Rats were given orally with different doses of ST-III active milk for 45 days. Before and after the test, the serum triglyceride content of the rats was tested for homogeneity of variance, and the homogeneity of variance was met. One-way ANOVA and multiple experiments were used. The two-two comparison method of the mean between the group and one control group was statistically processed. As can be seen from Table 4, there were no significant differences in serum triglycerides between the 21 ml/kg.bw, 42 ml/kg.bw, and 125 ml/kg.bw groups and the 0 mg/kg.bw group (P>0.05). Table 4 Effect of ST-III active milk on serum triglycerides ( ⁇ SD)
- Example 4 Effect of ST-III active milk on serum high-density lipoprotein cholesterol in rats. Different doses of ST-III active milk were administered orally to rats for 45 days, before and after the test. The rat serum high-density lipoprotein cholesterol content was tested for homogeneity of variance, and the homogeneity of variance was met. The one-way ANOVA method and the comparison method of the mean between multiple experimental groups and one control group were used for statistical processing. It can be seen from Table 5 that the serum high-density lipoprotein cholesterol in the 125 ml/kg.bw group was significantly higher than that in the Oml/kg.bw group (P ⁇ 0.01). Table 5 Effect of ST-III active milk on serum high-density lipoprotein cholesterol ⁇ SD)
- Lactobacillus plantarum ST-III CGMCC No. 0847 not only has a function of regulating blood fat, but also has a function of controlling or reducing body weight.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Mycology (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Microbiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Child & Adolescent Psychology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
L’invention concerne l’utilisation de la souche ST-III CGMCC No.0847 de Lactobacillum plantarun dans le cadre du contrôle ou de la perte de poids.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2004100668917A CN100422309C (zh) | 2004-09-29 | 2004-09-29 | 植物乳杆菌st-iii的减肥用途 |
| CN200410066891.7 | 2004-09-29 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2006034611A1 true WO2006034611A1 (fr) | 2006-04-06 |
Family
ID=36118560
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/CN2005/000101 WO2006034611A1 (fr) | 2004-09-29 | 2005-01-24 | Utilisation de la souche st-iii de lactobacillus plantarum dans la perte de poids |
Country Status (2)
| Country | Link |
|---|---|
| CN (1) | CN100422309C (fr) |
| WO (1) | WO2006034611A1 (fr) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102342327B (zh) * | 2011-10-21 | 2013-01-02 | 上海光明奶酪黄油有限公司 | 含益生菌的切达干酪及其制备方法 |
| CN103169075B (zh) * | 2011-12-21 | 2015-06-24 | 光明乳业股份有限公司 | 由植物乳杆菌ST-Ⅲ发酵的发酵豆制品和α-葡萄糖苷酶抑制剂 |
| CN102533790B (zh) * | 2011-12-23 | 2013-10-02 | 光明乳业股份有限公司 | 一种检测植物乳杆菌st-ⅲ的pcr检测方法及其引物和试剂盒 |
| CN102732470B (zh) * | 2012-07-20 | 2014-01-08 | 光明乳业股份有限公司 | 一种纯天然、低成本的植物乳杆菌st-ⅲ培养方法及其产品和应用 |
| CN103598594B (zh) * | 2013-10-28 | 2015-05-20 | 天津科技大学 | 植物乳杆菌在降血脂和辅助减肥方面的应用 |
| CN104928208B (zh) * | 2015-04-30 | 2020-04-10 | 江苏微康生物科技有限公司 | 一种植物乳杆菌Lp90及其筛选方法和应用 |
| CN105105145B (zh) * | 2015-09-14 | 2022-04-22 | 吉林省命之元生物科技有限公司 | 一株植物乳杆菌及其在制备降血糖血脂的功能性食品中的应用 |
| CN106720301A (zh) * | 2016-11-17 | 2017-05-31 | 光明乳业股份有限公司 | 一种巴氏杀菌乳及其制备方法 |
| TWI645854B (zh) * | 2017-03-20 | 2019-01-01 | 大江生醫股份有限公司 | 胚芽乳酸桿菌tci378及其於減脂及改善腸胃功能之應用 |
| CN107287133A (zh) * | 2017-06-26 | 2017-10-24 | 深圳华大三生园科技有限公司 | 一株植物乳杆菌lly‑606及其应用 |
| CN107897368A (zh) * | 2017-11-15 | 2018-04-13 | 光明乳业股份有限公司 | 一种益生菌发酵乳及其制备方法 |
| CN113598374A (zh) * | 2021-08-23 | 2021-11-05 | 东北农业大学 | 植物乳杆菌在减肥方面的应用 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1467290A (zh) * | 2003-04-11 | 2004-01-14 | 上海光明乳业股份有限公司 | 植物乳杆菌st-iii菌株及其在调节血脂方面的应用 |
-
2004
- 2004-09-29 CN CNB2004100668917A patent/CN100422309C/zh active Active
-
2005
- 2005-01-24 WO PCT/CN2005/000101 patent/WO2006034611A1/fr active Application Filing
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1467290A (zh) * | 2003-04-11 | 2004-01-14 | 上海光明乳业股份有限公司 | 植物乳杆菌st-iii菌株及其在调节血脂方面的应用 |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1754545A (zh) | 2006-04-05 |
| CN100422309C (zh) | 2008-10-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2006034611A1 (fr) | Utilisation de la souche st-iii de lactobacillus plantarum dans la perte de poids | |
| KR102000514B1 (ko) | 골다공증의 치료 또는 예방에 사용되는 프로바이오틱 스트레인 | |
| JP3668241B2 (ja) | 脂質代謝改善用組成物 | |
| Dudgeon et al. | Counteracting muscle wasting in HIV‐infected individuals | |
| EA015461B1 (ru) | Применение пробиотических бактерий в пищевых, кормовых и лечебных продуктах | |
| JP7366540B2 (ja) | メタボリックシンドローム治療用栄養補助食品および食品組成物 | |
| US20120141445A1 (en) | Nutrition for improving muscle strength in elderly | |
| MX2012009945A (es) | Preparacion que contiene bacteria de acido lactico. | |
| WO2011077800A1 (fr) | Agent permettant d'améliorer une hyperlipémie, composition permettant d'améliorer une anémie, composition permettant de réduire le taux d'acide urique et aliments et boissons | |
| CA2334877C (fr) | Supplement alimentaire derive de laits fermentes pour prevenir l'osteoporose | |
| WO2020063553A1 (fr) | Bifidobacterium lactis bl-99 et application associée | |
| EP4364583A1 (fr) | Composition comprenant trois souches de lactobacillus sp. et utilisation associée | |
| Kitchin et al. | Not just calcium and vitamin D: other nutritional considerations in osteoporosis | |
| WO2022269539A1 (fr) | Procédé pour favoriser le bien-être et faciliter la maîtrise de soi avant, pendant et/ou après un régime restrictif | |
| RU2491083C2 (ru) | Применение фитоэкдизонов и получение композиции для воздействия на метаболический синдром | |
| JPS62258323A (ja) | 血清コレステロ−ル上昇抑制剤 | |
| CN109527582A (zh) | 改进的食品组合物 | |
| CN109303115A (zh) | 生酮减肥代餐奶昔 | |
| CN105558244A (zh) | 一种辅助降血脂降血糖并提高免疫力的食品及其制备方法 | |
| KR20220097317A (ko) | 체지방 연소 촉진용 조성물 | |
| WO2014016265A1 (fr) | Aubépine et phytostérols et leurs effets sur les troubles métaboliques | |
| JP2006298783A (ja) | 免疫賦活組成物 | |
| WO2006093013A1 (fr) | Agent reduisant le cholesterol serique, son procede de production, et composition alimentaire et pharmaceutique agissant sur la reduction du cholesterol serique | |
| JP3248170B2 (ja) | コンドロイチン硫酸蛋白複合体含有食品 | |
| Yonei et al. | Effect and safety of Echigoshirayukidake (Basidiomycetes-X) on fatty liver: Stratified randomized, double-blind, parallel-group comparison study and safety evaluation study. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
| DPEN | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101) | ||
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| 122 | Ep: pct application non-entry in european phase |